Ziarco Appoints David L. Brinkley to the Board of Directors

| Print |
Thursday, 25 July 2013 09:00 (UTC + 2)

Ziarco logo

Canterbury, UK, July 25, 2013 / B3C newswire / – Ziarco, a biopharmaceutical company focusing on steroid-unresponsive inflammation and allergic diseases, has appointed the experienced pharma professional and recent Head of Business Development at Theravance, Mr. David Brinkley, to its board of directors. His role at Ziarco will be to provide input on the company's corporate, R&D strategy and business plans.

Commenting on his appointment, Mr. Brinkley said: "Ziarco’s assets have strong potential to yield differentiated, important new medicines to address unmet needs of patients across a spectrum of disorders. I look forward to assisting in the growth and success of the company.”

Ziarco’s CEO, Dr Mike Yeadon, commented: "We are delighted that David has joined our board and is providing valuable advice to the team. His substantial experience in new product planning, development of new medicines and business partnering are good compliments to the deep scientific expertise within Ziarco.  His insights will be invaluable to use as we drive our portfolio of preclinical and clinical programs forward."

Mr. Brinkley was Head of Business Development from November 2008 to July 2013 and had previously served as Senior Vice President, Commercial Development at Theravance from September 2000 through December 2007, when he left to start a consulting practice. From 1996 to 2000 he served as Worldwide Team Leader for Viagra at Pfizer Inc. leading the team that had full responsibility for the U.S. and subsequent global launch and marketing of Viagra. Mr. Brinkley joined Pfizer in 1995 through its acquisition of SmithKline Beecham's Animal Health operations and was Director of new product planning before leading the Viagra launch team. Mr. Brinkley held various management positions with SmithKline from 1983 to 1995. Mr. Brinkley holds an M.A. with honors in International Economics from the School of Advanced International Studies of the Johns Hopkins University and a B.A. in International Relations from Kent State University, where he graduated with University Honors.

 
About Ziarco
Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting inflammatory and allergic diseases. The company’s product pipeline includes a histamine H4 receptor antagonist programme with potential in multiple therapeutic areas, including chronic pruritus, inflammatory skin diseases, rheumatoid arthritis, psoriatic arthritis, asthma, allergic rhinitis  and pain. A lead H4 antagonist has completed a Phase 1 multiple ascending dose study.  A second clinical-stage programme targets inflammatory disorders by inhibiting cytosolic phospholipase A2 (cPLA2). The pipeline is completed by a histamine H3 receptor antagonist programme possessing CNS-sparing properties which is in advanced preclinical development and an early-stage spleen tyrosine kinase (SYK) inhibitor programme suitable for topical administration. Investors in Ziarco include Biotechnology Value Fund L.P. and other affiliates of BVF Partners L.P. and Pfizer Venture Investments.

 
Contact
Mike Yeadon
+44-1227-459119
This e-mail address is being protected from spambots. You need JavaScript enabled to view it